Their coadministration in NASH rats (NSG1) also lowered the serum ALT (42.12%), AST (64.44%), LDL/vLDL (58.35%), and TC (47.26%) compared to the treatment of vehicle (NC). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.